The Centre for Integrated Preclinical Drug Development (CIPDD) offers state-of-the art infrastructure required for bringing innovations into the drug development pathway facilitating candidate selection and optimisation that enable discovery researchers to progress their inventions across the 'Valley of Death' to the point where they will attract investment for commercialisation into products for improving human health.

The CIPDD's commercial arm is TetraQ. CIPDD/TetraQ is a leading GLP and ISO17025 (R&D) accredited provider of preclinical drug development capabilities and bioanalytical/pharmacokinetic (ADME) support for clinical trials - with data generated accepted by the FDA, EMA and the Australian Regulator - TGA. In addition, CIPDD/TetraQ undertakes research and testing of new analgesics in a large number of validated in vivo models of pain - an area of specialist expertise and headed by Professor Maree Smith.

All CIPDD/TetraQ staff and research higher degree students must adhere to the strict requirements of its quality system in order to ensure reproducibility and traceability of all research data.


CIPDD/TetraQ has ISO 17025(R&D) accreditation (ADME) and OECD-GLP recognition (ADME & Toxicology)

Year of establishment


Access and pricing 

For pricing information on the services below please contact Lawrence Bremner at or +61 (0)7 3346 7374.

Previous clients

Since commencement of operations in May 2005, CIPDD/TetraQ has conducted more than 500 R&D contracts for >200 industry and academic clients in the life science sector.



Bioanalytical infrastructure includes five AB Sciex LC-MS/MS instruments, 2 x Spark Holland robotic solid phase sample processing systems, GC/MS, GC-FID and HPLC instruments with UV and fluorescence detectors. All systems have been validated in accordance with 21CRF11 of the FDA.


  • Bioanalytical method development & validation
  • Pharmacokinetic & bioavailability studies
  • Metabolite identification & profiling

State-of-the-art animal facilities, toxicology and efficacy study capabilities, including ProvantisTM for the GLP data management and GLP biochem/haematology equipment.


  • Testing the analgesic properties of new compounds in a range of different neuropathic and nociceptive pain associated with a number of diseases and conditions (post-surgical pain, post herpetic pain, prostate cancer induced bone cancer pain, diabetic pain, chemotherapy induced pain etc.)
  • Undertaking mechanism of action studies of new analgenics.


  • Genotoxicity assays (AMES, MLA, Micronucleus)
  • Dose range finding
  • Repeat dose
  • Safety Pharmacology